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There is increasing evidence that the fast-inactivating potassium current IA, encoded
by KV3. 4 channels, plays an important role in Alzheimer’s Disease (AD), since the
neurotoxic β-amyloid peptide1-42 (Aβ1−42) increases the IA current triggering apoptotic
processes. The specific inhibition of KV3.4 by the marine toxin extracted from Anemonia
sulcata, named blood depressing substance-I (BDS-I), reverts the Aβ peptide-induced
cell death. The aim of the present study was to identify the smallest fragments of
BDS-I, obtained by peptide synthesis, able to inhibit KV3.4 currents. For this purpose,
whole-cell patch clamp technique was used to evaluate the effects of BDS-I fragments on
KV3.4 currents in CHO cells heterologously expressing KV3.4. We found that BDS-I[1-8]
fragment, containing the N-terminal octapeptide sequence of full length BDS-I, was able
to inhibit KV3.4 currents in a concentration dependent manner, whereas the scrambled
sequence of BDS-I[1-8] and all the other fragments obtained from BDS-I full length
were ineffective. As we demonstrated in a previous study, BDS-I full length is able to
counteract Aβ1−42-induced enhancement of KV3.4 activity, preventing Aβ1−42-induced
caspase-3 activation and the abnormal nuclear morphology in NGF-differentiated PC-12
cells. Similarly to BDS-I, we found that BDS-I[1-8] blocking KV3.4 currents prevented
Aβ1−42-induced caspase-3 activation and apoptotic processes. Collectively, these
results suggest that BDS-I[1-8] could represent a lead compound to be developed as a
new drug targeting KV3.4 channels.
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INTRODUCTION
Voltage-gated potassium (KV) channels are transmembrane proteins with strong selectivity for
K+ ions and sensitivity to voltage changes. In neuronal cells, KV channels are key regulators
of membrane excitability, resting membrane potentials and spontaneous firing rate, action
potential waveform and duration, neurotransmitter release, and apoptosis (Rudy et al., 1999).
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Several neuronal populations in the central nervous system
(CNS) are required to generate action potentials with high
frequency (Coetzee et al., 1999). KV channels of the KV3
family are prominently expressed in these neurons and have
a central role in facilitating sustained and/or repetitive high
frequency firing (Moreno et al., 2001). The subunits of the
KV3 Shaw-related subfamily (KV3.1-KV3.4), assembled into
homotetramers with identical subunits or heterotetramers with
different subunits, display unique biophysical properties such as
high thresholds of activation, rapid activation and deactivation
kinetics and relatively large conductance (Coetzee et al., 1999;
Rudy et al., 1999). In rodents, three of four known KV3 genes
(KV3.1-KV3.3) are conspicuously expressed in the CNS, whereas
KV3.4 transcripts are abundant in skeletal muscle, sympathetic
neurons, and weakly expressed in a few neuronal types in the
brain in physiological conditions (Heinemann et al., 1996; Rudy
et al., 1999). On the other hand, many evidence have been
provided revealing the increase of KV3.4 protein expression in
several pathological conditions such as hypoxia (Kaab et al.,
2005), oxidative stress (Song et al., 2017), and neurodegeneration
(Baranauskas et al., 2003; Angulo et al., 2004; Boscia et al., 2017).
Moreover, among the KV3 subfamily, only the KV3.4 channel
carries the fast inactivating potassium currents IA and exhibits
peculiar pharmacological characteristics. In fact, similarly to
the other KV3 channels, KV3.4-mediated currents are highly
sensitive to external tetraethylammonium or 4-aminopyridine
and, in addition, a selective responsiveness of KV3.4 to some
toxins have been reported. In this regard, Diochot et al. reported
that two 43-amino acid peptides from the sea anemoneAnemonia
sulcata, the blood depressing substance (BDS)-I and BDS-II,
show a specific blocking activity against the IA mediated by this
channel (Diochot et al., 1998). These toxins directly inhibit KV3.4
channels in a reversible manner, with a similar IC50 (Diochot
et al., 1998), despite a difference in the time-dependence of their
effect has been suggested (Diochot et al., 1998; Song et al., 2017).
Another aspect that deserves amention is that the drug sensitivity
of KV3.4 pore-forming α subunit, as well as its gating kinetics,
conductance and ion selectivity, is modulated by the interaction
with its accessory β subunit, the MinK-related peptide 2 (MiRP2)
(Abbott et al., 2001; McCrossan and Abbott, 2004).
The IA currents mediated by KV3.4 channel subunits have
been recognized as a relevant player in Alzheimer’s disease
(AD) and are now emerging as a new target candidate for
AD (Angulo et al., 2004; Pannaccione et al., 2005, 2007; Boda
et al., 2012; Boscia et al., 2017). In previous studies, we
demonstrated that β-amyloid peptide 1-42 (Aβ1−42) alters the
properties of K+ currents in primary hippocampal neurons
(Pannaccione et al., 2005) through the selective up-regulation of
KV3.4 channels mediated by the activation of the transcriptional
factor NF-κB (Pannaccione et al., 2007). Moreover, we also
reported an increase in cell death caused by the reduction
of cytoplasmic K+ concentrations, because of the enhanced
expression and function of this K+ channel upon Aβ1−42
exposure (Pannaccione et al., 2007). In addition, it has been
demonstrated the correlation between altered intracellular K+
concentrations and apoptotic processes (Yu, 2003). Interestingly,
the concept that KV3.4 channels are involved in the Aβ1−42
neurotoxic effects (Abbott et al., 2001) was further supported
by our results showing that BDS-I treatment, by blocking
the KV3.4 channel, prevents the apoptotic cascade triggered
by Aβ1−42 fragment in hippocampal neurons, thus exerting
a potent neuroprotective action (Pannaccione et al., 2007).
Importantly, these previous results identified the KV3.4 channel
as a new molecular target, thus revealing a possible new
strategy in the scenario of pharmacological therapies against
AD progression.
For these reasons, the main goal of the present study has been
to identify the smallest BDS-I amino acid sequence able to exert a
neuroprotective effect by blocking KV3.4 activity and to provide
a new opportunity in the development of potential drugs for
AD treatment.
MATERIALS AND METHODS
Materials
Fmoc-protected amino acids, Rink amide resin, and coupling
reagents for SPPS compatibility, all were purchased from GL
Biochem (Shanghai, China). Common solvents for SPPS and
HPLC purification and characterization were obtained from
VWR (Milano, Italy), whereas trifluoroacetic acid (TFA) was
purchased from Iris Biotech GmbH (Marktredwitz, Germany).
Other unmentioned materials were from Sigma Chemicals
(St. Louis, MO, USA). Rabbit polyclonal anti-KV3.4, rabbit
polyclonal anti-MiRP2, NGF 2.5S, TTX, nimodipine were from
Alomone Labs (Jerusalem, Israel). Rabbit polyclonal anti-cleaved
caspase-3 and rabbit monoclonal anti-Aβ were purchased from
Cell Signaling (Massachusetts, USA). DMEM, FBS, non-essential
amino acids, penicillin, streptomycin, and PBS were from Gibco-
BRL (Grand Island, NY, USA). Lipofectamine 2000 was from
Invitrogen Corp (Carlsbad, CA, USA). The Aβ1−42 peptide was
synthesized by INBIOS (Pozzuoli, Naples, Italy). The BDS-I
TABLE 1 | Peptide library on BDS-I sequence. BDS-I[1-8], BDS-I[7-14],
BDS-I[13-20], BDS-I[19-26], BDS-I[25-32], BDS-I[31-38], BDS-I[37-43], and
BDS-I[1-8scr] peptides were designed following the mimotopic strategy.
Code Sequence
BDS-I[1-43] AAPCFCSGKPGRGDLWILRGTCPGGYGYTSNCYKWPNICCYPH
*BDS-I[1-43] AAPAFASGKPGRGDLWILRGTAPGGYGYTSNAYKWPNIAAYPH
BDS-I[1-8] H-Ala-Ala-Pro-Ala-Phe-Ala-Ser-Gly-OH
BDS-I[7-14] H-Ser-Gly-Lys-Pro-Gly-Arg-Gly-Asp-OH
BDS-I[13-20] H-Gly-Asp-Leu-Trp-Ile-Leu-Arg-Gly-OH
BDS-I[19-26] H-Arg-Gly-Thr-Ala-Pro-Gly-Gly-Tyr-OH
BDS-I[25-32] H-Gly-Tyr-Gly-Tyr-Thr-Ser-Asn-Ala-OH
BDS-I[31-38] H-Asn-Ala-Tyr-Lys-Trp-Pro-Asn-Ile-OH
BDS-I[37-43] H-Asn-Ile-Ala-Ala-Tyr-Pro-His-OH
BDS-I[1-8scr] H-Gly-Ser-Ala-Phe-Ala-Pro-Ala-Ala-OH
The synthesis was based on BDS-I full length sequence replacing the cysteine in position
4, 6, 22, 32, 39, and 40 by alanine order to prevent the formation of disulphide
bonds and to obtain unfolded peptides. We obtained a small library characterized by
overlapping peptides of equal length, containing 8 amino acids, except for the sequence
BDS-I[37-43].*BDS-I[1-43] with cysteine→lanine substitution.
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toxin and BDS-I fragments, BDS-I[1-8], BDS-I[1-8scr], BDS-
I[7-14], BDS-I[13-20], BDS-I[19-26], BDS-I[25-32], BDS-I[31-
38], BDS-I[37-44], were synthesized by Prof Paolo Grieco
from Dept. of Pharmacy, University of Naples “Federico II,”
Naples, Italy. Non-fat dry milk and precast gels 4-20% were
from Bio-Rad Laboratories (Milan, Italy). Protease Inhibitor
Cocktail II was from Roche Diagnostic (Monza, Italy). Glass
coverslips were from Carolina Biological Supply Company
(Burlington, NC, USA). The nitrocellulose membranes and
ECL Western Detection Kit were from Amersham Bioscience
(Buckinghamshire, UK).
Heterologous Expression of KV3.4 and
MiRP2 cDNAs
KV3.4 and MiRP2 channel subunits were expressed in Chinese
hamster ovary (CHO) cells by transient transfection. CHO
FIGURE 1 | Heterologous expression of KV3.4 and MiRP2 cDNAs in CHO cells. (A) Representative western blot of KV3.4 and MiRP2 protein expression in CHO cells
under control condition and transiently transfected with KV3.4 and MiRP2 cDNAs. (B) Representative traces of KV3.4 currents recorded in CHO cells under control
condition and transiently transfected with KV3.4 and MiRP2 cDNAs.
FIGURE 2 | Screening of BDS-I fragments ‘activity on Kv3.4 currents by patch clamp technique. (A) Representative traces of Kv3.4 currents recorded in CHO cells
transiently transfected with Kv3.4\MiRP2 cDNAs 24 h after the transfection. Each cell has been recorded under control condition and after exposure to 100 nM of the
indicated BDS-I fragments (BDS-I[1-8], BDS-I[7-14], BDS-I[13-20], BDS-I[19-26], BDS-I[25-32], BDS-I[31-38], BDS-I[37-43]) and full BDS-I, added to the extracellular
solution. The switch to the extracellular solution containing each specific peptide represented the start of the treatment. For each groups the traces show Kv3.4
currents elicited by depolarizing steps of increasing voltages from −80 to +60mV (20mV of increments), preceded by a conditioning prepulse at −100mV. (B)
Quantification of the % of inhibition of Kv3.4 current densities exerted by BDS-I fragments, at the peak of the depolirizing pulse (+60mV) represented in A.
Quantification of Kv3.4 currents inhibition. Values are expressed as % of inhibition, obtained as [(C0-C1)/C0] × 100 where C0 is Kv3.4 control current; C1 is Kv3.4
current in the presence of BDS-I fragments. Values are expressed as percentage mean±SEM from 6 to 10 cells per experimental group of three independent
experimental sessions. Statistical comparisons between groups were performed by one-way ANOVA followed by Newman-Keuls’ test; ***p < 0.001 vs. control;
#p < 0.01 vs. BDS-I full length.
Frontiers in Chemistry | www.frontiersin.org 3 July 2019 | Volume 7 | Article 479
Ciccone et al. BDS-I[1-8] as New Kv3.4 Inhibitor
FIGURE 3 | Effect of BDS-I[1-8] fragment on KV3.4 currents in CHO cells transiently transfected with KV3.4 and MiRP2 (A) Representative traces of KV3.4 currents
recorded in CHO cells under control condition and in the presence of BDS-I[1-8] (100 nM). (B) Inhibitory dose-response curves to determine the IC50 for BDS-I[1-8] on
KV3.4 currents. The inhibitory dose-response curve data were plotted as % of inhibition normalized to controls with applied curve fits calculated using GraphPad
Prism. (C) Time-course of outward K+ currents recorded in CHO cells transfected with KV3.4 and MiRP2 exposed to 100 nM BDS-I[1-8]. The currents were
measured at the peak of repetitive (20 sec) depolarizing pulses (+60mV) were plotted vs. time. (D) Representative current-voltage (I-V) relationship for KV3.4 peak
current measured before and during application of 100 nM BDS-I[1-8]. Currents were induced by a set of depolarizing pulses from +60 to −100mV (in 20mV steps).
(E) Representative steady-state activation and inactivation curves of KV3.4 channels under control condition and in the presence of BDS-I[1-8] (100 nM). For the
voltage-dependent activation the currents recorded upon repolarization to −100mV were measured, normalized to the maximum value, and plotted vs. the
membrane voltage of the depolarizing step. For the inactivation curves, the initial currents recorded immediately after delivering the +80-mV test pulse were
measured, normalized to the maximum value, and plotted vs. the membrane voltage of the conditioning pulses. The experimental data were fitted to the following
form of the Boltzmann equation: gKv = max/(1 + exp(V½-V )/k), where V is the test potential, V½ is the half-activation potential, and k (or kT/ze) is the slope of the
conductance to voltage relationship.
cells were grown in 100mm plastic Petri dishes in Dulbecco’s
Modified Eagle Medium containing 10% fetal bovine serum
(FBS), non-essential amino acids (0.1mm), penicillin (50 U/ml),
and streptomycin (50µg/ml) in a humidified atmosphere
at 37◦C with 5% CO2 (Miceli et al., 2015). KV3.4 and
MiRP2 cDNAs were kindly provided by the Professor
Goldstein of the Department of Pediatrics and Institute for
Molecular Pediatric Sciences, University of Chicago, USA.
For electrophysiological experiments, cells were seeded on
glass cover-slips (Glaswarenfabrik Karl Hecht KG, Sondheim,
Germany) coated with poly-L-lysine (50µg/mL) and transfected
the next day with the appropriate cDNAs using Lipofectamine
2000 according to guidelines for transfection. We performed
electrophysiological experiments 48 h after transfection.
Cell Culture
Rat pheochromocytoma cells (PC-12 cells) were grown as
previously described (Pannaccione et al., 2005, 2007). For all the
experiments, cells were seeded at low density on glass cover-
slips coated with poly-L-lysine (50µg/ml). Differentiation of PC-
12 cells was achieved by treatment with neuronal growth factor
(NGF) 2.5 S (50 ng/ml) for 7–9 days (Greene and Tischler, 1976).
For electrophysiological experiments, cells were seeded on glass
cover-slips and used after 7–9 days of NGF.
Whole-Cell Electrophysiology
Currents from CHO cells were recorded at room temperature
1-2 days after transfection. The extracellular solution contained
the following (in mM): 138 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2,
10 glucose and 10 HEPES, adjusted pH 7.4 with NaOH. The
pipette solution contained (in mM) the following: 140 KCl, 2
MgCl2, 10 EGTA, 10 HEPES, 5 Mg-ATP, adjusted pH 7.4 with
KOH (Miceli et al., 2015). KV3.4 currents were measured by
applying voltage steps from−100mV to+60mV from a holding
potential of −80mV (Abbott et al., 2001). Moreover, the total
outward K+ currents were recorded in NGF-differentiated PC-12
cells using the extracellular solution contained the following (in
mM): 150 NaCl, 5.4 KCl, 3 CaCl2, 1 MgCl2, 10 HEPES, adjusted
pH 7.4 with NaOH. The pipette solution contained the following
(in mM): 140 KCl, 2 MgCl2, 10 HEPES, 10 glucose, 10 EGTA,
and 1 Mg-ATP adjusted at pH 7.4 with KOH (Diochot et al.,
1998). All experiments were performed in the presence of 50 nM
tetrodotoxin (TTX) and 10µ M nimodipine in the extracellular
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FIGURE 4 | Effect of BDS-I[1-8scr] fragment on Kv3.4 currents in CHO cells transfected with Kv3.4 and MiRP2. (A) Representative traces of Kv3.4 currents recorded
in CHO cells under control condition and in the presence of BDS-I[1-8scr] 100 nM. Each cell has been recorded under control condition and after exposure to 100 nM
of BDS-I[1-8scr] added to the extracellular solution. The switch to the extracellular solution containing each specific peptide represented the start of the treatment. For
each groups the traces show Kv3.4 currents elicited by depolarizing steps of increasing voltages from −80 to +60mV (20mV of increments), preceded by a
conditioning prepulse at −100mV. (B) Quantification of the % of inhibition of Kv3.4 current densities exerted by BDS-I fragments, at +60mV represented in A.
Quantification of Kv3.4 current inhibition. Values are expressed as % of inhibition, obtained as [(C0-C1)/C0] × 100 where C0 is Kv3.4 control current; C1 is Kv3.4
current in the presence of BDS-I[1-8scr]. Values are expressed as percentage mean±SEM from 6 to 10 cells per experimental group of 3 independent experimental
sessions. Statistical comparisons between groups were performed by one-way ANOVA followed by Newman-Keuls’ test; ***p < 0.001 vs. control. (C) Time-course of
outward K+ currents recorded in CHO cells transfected with Kv3.4 and MiRP2 exposed to 100 nM BDS-I[1-8scr]. The currents were measured at the peak of
repetitive (20 s) depolarizing pulses (+60mV) were plotted vs. time.
solution. To discriminate K+ current components appropriate
electrophysiological protocols were used (Pannaccione et al.,
2007). Steady-state activation and inactivation properties were
measured by using appropriate protocols (Pannaccione et al.,
2005). Capacitive currents were elicited by 5-mV depolarizing
pulses from −80mV and acquired at a sampling rate of 50 kHz.
The capacitance of the membrane was calculated according to
the following equation: Cm = τc · Io/1Em (1-I∞/Io), where
Cm is membrane capacitance, τc is the time constant of the
membrane capacitance, Io is the maximum capacitance current
value, 1Em is the amplitude of the voltage step, and I∞ is the
amplitude of the steady-state current. K+ currents were recorded
by patch-clamp technique in CHO and NGF-differentiated PC-
12 cells using a commercially available amplifier (Axopatch 200B,
Molecular Devices) and Digidata 1322A interface (Molecular
Devices, USA). The whole-cell configuration of the patch-clamp
technique was adopted using glassmicropipettes with a resistance
of 2.5-5.0 M. Data were acquired and analyzed using the
pClamp software (version 9, Molecular Devices).
BDS-I Fragments Synthesis
Peptides BDS-I[1-8], BDS-I[13-20], BDS-I[19-26], BDS-I[25-32],
BDS-I[31-38], BDS-I[37-43], and BDS-I[1-8scr] were designed
following the mimotopic strategy (Table 1). All compounds
were synthesized manually by adopting a standard solid-phase
peptide synthesis (SPPS) using the Fmoc/tBu orthogonal strategy
(Merrifield, 1963; Carpino and Han, 1970; Merlino et al.,
2016). The use of the Wang resin 0.7 mmol/g (GL Biochem,
Shanghai, China) as solid support in the entire synthesis
resulted in amidated C-terminal peptides after TFA-mediated
cleavage (TFA/TIS/H2O, 95:2.5:2.5, 3 h). The crude peptides
were purified by reverse-phase HPLC (RP-HPLC, Shimadzu
Nexera) on a preparative column (PhenomenexKinetex, C18
column, 150 × 21.2mm, 5µm, 100 Å) using a linear
gradient of acetonitrile (0.1% TFA) in water (0.1% TFA),
from 10 to 90% over 20min, with a flow rate of 10.0
mL/min and UV detection at 220 nm. The purity (>98%) was
ascertained by analytical RP-HPLC on a PhenomenexKinetex
C18 column (150 × 4.6mm, 5µm, 100 Å) and molecular
weights of all peptides were confirmed by LC-ESI MS system
(Agilent Technology).
BDS-I[1-8]: AAPAFASG-OH, (3.2mg, yield 31%, purity
>98%), observed mass 690.75 (M+H)1+, calculated
mass 691.32.
BDS-I[7-14]: GKPGRGDL-OH, (2.8mg, yield 27%,
purity >98%), observed mass 798.89 (M+H)1+, calculated
mass 799.03.
BDS-I[13-20]: GDLWILRG-OH, (4.2mg, yield 34%,
purity >98%), observed mass 929.08 (M+H)1+, calculated
mass 929.76.
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FIGURE 5 | Effect of BDS-I[1-8] fragment on KV3.4 currents in NGF-differentiated PC-12 cells under control condition and exposed to Aβ1−42. (A) Representative
traces of KV3.4 currents recorded in NGF-differentiated PC-12 cells under control condition and exposed to 100 nM of BDS-I[1-8] (top); representative traces of KV3.4
currents recorded in NGF-differentiated PC-12 cells exposed to Aβ1−42 oligomers (5µM for 24 h) in the absence and in the presence of BDS-I[1-8] fragment (30min
of pre-treatment before adding Aβ1−42 oligomers) (bottom). For each group, traces show KV3.4 currents elicited by depolarizing steps of increasing voltages from
−80 to +40mV (20mV of increments), preceded by a conditioning prepulse at −100mV. (B) Quantification of KV3.4 current densities, at the peak of the depolirizing
pulse (+40mV) represented in A. Values are expressed as percentage mean±SEM from 6 to 10 cells per experimental group of 3 independent experimental sessions.
Statistical comparisons between groups were performed by one-way ANOVA followed by Newman-Keuls’ test; **p < 0.01 vs. control; ∧ p < 0.01 vs. Aβ1−42.
BDS-I[19-26]: RGTAPGGY-OH, (3.4mg, yield 25%,
purity >98%), observed mass 777.83 (M+H)1+, calculated
mass 778.21.
BDS-I[25-32]: GYGYTSNAY-OH, (5.7mg, yield 38%,
purity >98%), observed mass 995.00 (M+H)1+, calculated
mass 995.67.
BDS-I[31-38]: NAYKWPNI-OH, (4.6mg, yield 30%,
purity >98%), observed mass 1005.13 (M+H)1+, calculated
mass 1005.90.
BDS-I[37-43]: NIAAYPH-OH, (5.1mg, yield 41%,
purity >98%), observed mass 784.86 (M+H)1+, calculated
mass 784.97.
BDS-I[1-8scr]: GSAFAPAA-OH, (2.4mg, yield 43%, purity >
98%), observed mass 690.77 (M+H)1+, calculated mass 691.32.
BDS-I Fragment Application
All BDS-I fragments, BDS-I[1-8], BDS-I[7-14], BDS-I[13-20],
BDS-I[19-26], BDS-I[25-32], BDS-I[31-38], BDS-I[37-43] as well
as the negative control peptide BDS-I[1-8scr] have been applied
by acute treatment.
For the acute treatment, each peptide has been added in
the extracellular solution. For each cell, we first recorded
K+ currents as previously described, in the absence of
peptides. After that, we switched from the extracellular
solution without BDS-I peptides to the extracellular solution
containing the BDS-I peptide. In these conditions, we
recorded K+ currents until the steady-state was reached.
This protocol has been performed to test the effect
on KV3.4 currents of each BDS-I fragment as well as
of BDS-I[1-8scr].
To evaluate the effect of the active fragments in the presence
of Aβ1−42 oligomers, we pre-treated cells by adding the fragment
in the culture medium at the final concentration of 100 nM,
30min before exposing cells to Aβ1−42 oligomers and lasted
for 24 h.
Assessment of Nuclear Morphology
Nuclear morphology was evaluated by using the fluorescent
DNA-binding dye Hoechst-33258 already described
(Pannaccione et al., 2007).
Western-Blot Analysis
NGF-differentiated PC-12 and CHO cells were washed in
phosphate buffered saline (PBS) and collected by gentle scraping
in ice-cold RIPA buffer containing in mM: 50 Tris pH 7.4,
100 NaCl, 1 EGTA, 1 PMSF, 1 sodium orthovanadate, 1 NaF,
0.5% NP-40, and 0.2% SDS supplemented with protease inhibitor
cocktail II. After sonication and incubation for 1 h on ice, we
centrifuged at 12,000 rpm at 4◦C for 30min and collected the
supernatants. The protein content of resulting supernatant was
determined using the Bradford reagent. Hundred microgram of
proteins were mixed with a Laemmli sample buffer; then, they
are applied and resolved on SDS-PAGE polyacrylamide gels.
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FIGURE 6 | BDS-I[1-8scr] fragment on KV3.4 currents in NGF-differentiated PC-12 cells. (A) Representative traces of KV3.4 currents recorded in NGF-differentiated
PC-12 cells under control condition and exposed for 24 h to 100 nM BDS-I[1-8scr] (top); representative traces of KV3.4 currents recorded in NGF-differentiated PC-12
cells exposed to Aβ1−42 oligomers (5µM, 24 h) in the absence and in the presence of BDS-I[1-8scr] fragment (30min of pre-treatment before adding Aβ1−42
oligomers) (bottom). For each groups the traces show KV3.4 currents elicited by depolarizing steps of increasing voltages from −80 to +40mV (20mV of increments),
preceded by a conditioning prepulse at −100mV. (B) Quantification of KV3.4 current densities, at the peak of the depolirizing pulse (+40mV) represented in A. Values
are expressed as percentage mean±SEM from 6 to 10 cells per experimental group of 3 independent experimental sessions. Statistical comparisons between groups
were performed by one-way ANOVA followed by Newman-Keuls’ test; **p < 0.01 vs. control.
Following transfer onto nitrocellulose membranes, non-specific
binding sites were blocked by incubation for 2 h at 4◦C with 5%
non-fat dry milk in TBS-T buffer; subsequently, incubated with
primary antibodies overnight at 4◦C. After three washes with
TBS-T, the membranes were incubated 1 h with the appropriate
secondary antibody. Excessive antibodies were then washed
away three times (10min) with TBS-T. Proteins were visualized
with peroxidase-conjugated secondary antibodies, using the
enhanced chemiluminescence system. The software Image J
(NIH, Bethesda, MA, USA) was used for densitometric analysis.
Primary antibodies were: rabbit polyclonal anti-KV3.4 (1:1,000),
rabbit polyclonal anti-MiRP2 (1:1,000), rabbit polyclonal anti-
cleaved caspase-3 (1:1,000) and mouse monoclonal anti-α-
Tubulin (1:3,000).
Aβ Treatments
The peptide used in our study was synthesized by INBIOS
(Pozzuoli, Naples, Italy) using the Aβ1−42 sequence of
human APP [UniProtKB-P05067 (A4_HUMAN)]. The purity
of the peptide was assessed by high-performance liquid
chromatography (>95% pure) and the amino acid composition
was verified by mass spectrometry. The Aβ oligomers was
resuspended in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP;
Sigma, Milan, Italy), at a final concentration of 1mM. Then,
the preparation was aliquoted, microcentrifugeted, dried by
SpeedVac and stored at −20◦C. Before their use, Aβ oligomer
aliquots were first resuspended in dimethyl sulfoxide (DMSO)
at a final concentration of 5mM, and then diluted in ice-cold
cell culture medium (phenol red-free Ham’s F-12, Sigma,
Milan, Italy), to the final concentration of 100µM. Next,
after vortexing for 30 sec, the resuspension was incubated for
24 h at 4◦C. Finally, the solution was centrifuged at 14,000
rpm at 4◦C for 10min, and the supernatant, containing
Aβ1−42oligomers, aliquoted and stored at −20◦C (Stine et al.,
2003). Aβ1−42were added to the culture medium at the final
concentration of 5µM for 24 h. The pre-aggregated preparation
of Aβ oligomers was analyzed in SDS-PAGE using the rabbit
monoclonal anti-Aβ on precast gels 4-20%. Oligomers between
4 and 15 kDa were the major species of the Aβ oligomers in
the preparation.
Data and Statistical Analysis
GraphPad Prism 6.02 was used for statistical analyses (GraphPad
Software, La Jolla, CA). The data are expressed as the
mean ± S.E.M. of the values obtained from individual
experiments. Statistical comparisons between groups were
performed by Student’s t-test or one-way analysis of variance
(ANOVA) followed by Newman-Keuls’ test; p < 0.05 was
considered significant.
Frontiers in Chemistry | www.frontiersin.org 7 July 2019 | Volume 7 | Article 479
Ciccone et al. BDS-I[1-8] as New Kv3.4 Inhibitor
FIGURE 7 | Effect of BDS-I[1-8] on Aβ1−42-induced abnormal nuclear morphology and caspase-3 activation in NGF-differentiated PC-12 cells. (A) Assessment of
nuclear morphology with Hoechst-33258 in NGF-differentiated PC-12 cells under control condition and exposed to Aβ1−42 oligomers (5µM, 24 h) in the absence and
in the presence of BDS-I[1-8] fragment, BDS-I[1-8scr] fragment, BDS-I full length (3 h of pre-treatment before adding Aβ1−42 oligomers) (top). Quantification of the
percentage of abnormal nuclei in NGF-differentiated PC-12 cells under control condition and exposed to Aβ1−42 oligomers (5µM, 24 h) in the absence and in the
presence of BDS-I[1-8] fragment, BDS-I[1-8scr] fragment, BDS-I full length (30min of pre-treatment before adding Aβ1−42 oligomers) obtained in 3 separate
experiments in which at least 10 microscopic fields were analyzed (∼1,000 cells per group) (Bottom). Statistical comparisons between groups were performed by
one-way ANOVA followed by Newman-Keuls’ test; ***p < 0.001 vs. control; ∧ p < 0.01 vs. Aβ1−42. (B) Representative western blot (top) and densitometric
quantification (bottom) of caspase-3 protein expression in NGF-differentiated PC-12 cells under control condition and exposed to Aβ1−42 oligomers (5µM, 24 h) in
the absence and in the presence of BDS-I[1-8] fragment, BDS-I[1-8scr] fragment, BDS-I full length (30min of pre-treatment before adding Aβ1−42 oligomers). Values
are expressed as mean±SEM of 3 independent experimental sessions. Statistical comparisons between groups were performed by one-way ANOVA followed by
Newman-Keuls’ test; ***p < 0.001 vs. control; ∧ p < 0.01 vs. Aβ1−42.
RESULTS
Synthesis of BDS-I Fragments
To identify the key amino acidic residues of BDS-I essential
for its inhibitory action on KV3.4 channels, we performed
an overlapping peptide library on BDS-I sequence (Table 1).
This small library is characterized by overlapping peptides
of equal length, containing 8 amino acids, except for the
sequence BDS-I[37-43]. Moreover, the cysteine in position
4, 6, 22, 32, 39, and 40 in the sequence of BDS-I[1-43],
presumably involved in the tertiary structure of BDS-I, have
been replaced by alanine in order to prevent the formation
of disulphide bonds and to obtain unfolded peptides. This
approach allowed us to focus on the importance of the
amino acid sequence rather than the tertiary structure of
BDS-I fragments.
Screening of BDS-I Fragments ‘Activity on
KV3.4 Currents by Patch Clamp Technique
To identify the smallest BDS-I amino acid sequence able to
block Kv3.4 activity, we evaluated the effect of the newly
synthesized BDS-I fragments in CHO cells transiently transfected
with Kv3.4/MiRP2, by patch clamp technique in whole cell
configuration. Kv3.4 expression and activity in transfected
CHO cells were monitored by western blot analysis and
electrophysiological experiments, respectively (Figures 1A,B).
After acute application of the peptides, we found that only BDS-
I[1-8] fragment (100 nM), containing the N-terminal octapeptide
sequence of full length BDS-I, similarly to the full length, was able
to inhibit Kv3.4 currents (Figures 2A,B), whereas the other BDS-
I fragments, BDS-I[7-14], BDS-I[13-20], BDS-I[19-26], BDS-
I[25-32], BDS-I[31-38], and BDS-I[37-44] (100 nM) did not
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(Figures 2A,B, 3A). The percentage of inhibition of Kv3.4
currents exerted by BDS-I[1-8] fragment (100 nM) was more
than 80%. Interestingly, BDS-I, displaying a percentage of
inhibition of ∼60%, appeared less effective than BDS-I[1-8]
fragment (Figure 2B). Moreover, we found that BDS-I[1-8]
reduced Kv3.4 currents in a concentration-dependent manner,
with an IC50 value of 75 nM (Figure 3B). The time-course
of the effect of BDS-I[1-8] on Kv3.4 currents showed that
the steady-state of inhibition was reached at 150 s of peptide
exposure (Figure 3C). Inhibition of the Kv3.4 current induced
by BDS-I[1-8] was not voltage-dependent as evidenced by I-V
relationship for Kv3.4 peak current measured before and during
application of 100 nM BDS-I[1-8] (Figure 3D). Furthermore,
BDS-I[1-8] treatment did not modify the steady-state parameters
for the activation and inactivation of Kv3.4 currents (Figure 3E).
Effect of BDS-I[1-8] Scrambled Peptide on
Kv3.4 Currents
To confirm that the inhibitory effect of BDS-I[1-8] on
KV3.4 currents was sequence-specific, we synthesized
a peptide with the scrambled sequence of BDS-I[1-8],
named BDS-I[1-8scr]. Electrophysiological experiments
performed in CHO cells transiently transfected with
KV3.4/MiRP2 showed that BDS-I[1-8scr] at the same
concentration of 100 nM was not able to modify KV3.4
activity (Figures 4A,B). The time-course of current
inhibition during BDS-I[1-8scr] exposure is presented
in Figure 4C.
Effect of BDS-I[1-8] on Aβ1−42-Induced
Upregulation of Kv3.4 Activity and
Caspase-3 Activation in NGF-Differentiated
PC-12 Cells
Analogously to the results obtained in CHO cells, BDS-I[1-8]
fragment blocked KV3.4 activity in NGF-differentiated PC-
12 cells (Figures 5A,B). Importantly, like BDS-I, BDS-I[1-8]
fragment prevented the KV3.4 upregulation elicited by Aβ1−42
exposure (5µM for 24 h) (Figures 5A,B). By contrast, BDS-I[1-
8scr] did not counteract Aβ1−42-induced KV3.4 upregulation
(Figures 6A,B). More interestingly, nuclear morphological
studies by bisbenzimide Hoechst staining highlighted that,
similar to the full length BDS-I, BDS-I[1-8], but not BDS-I[1-
8scr], was able to significantly prevent the abnormal nuclear
morphology induced by Aβ1−42 exposure in NGF-differentiated
PC-12 cells (Figures 7A,B). These results were confirmed by
western blot analysis of activated caspase-3. In fact, BDS-I[1-8]
prevented Aβ1−42-induced caspase-3 activation whereas BDS-
I[1-8scr] did not (Figure 7C).
DISCUSSION
In this study, a novel peptide obtained from the sequence of
the sea anemone toxin BDS-I has been successfully identified
as a new inhibitor of the KV3.4 channel subunits. In fact,
BDS-I[1-8] fragment, containing the N-terminal octapeptide
sequence of full length BDS-I, was able to inhibit KV3.4 currents
in a concentration dependent manner, with an IC50 value of
75 nM, in CHO cells transiently transfected with KV3.4/MiRP2.
Interestingly, the other BDS-I fragments, BDS-I[7-14], BDS-I[13-
20], BDS-I[19-26], BDS-I[25-32], BDS-I[31-38], BDS-I[37-44],
failed to modulate KV3.4 activity, thus confirming the key role
played by the N-terminal octapeptide sequence of BDS-I in
its pharmacological effect on KV3.4 currents. To confirm and
validate the results obtained with BDS-I[1-8], we synthesized
a scramble sequence of this peptide, as reported in Table 1.
Importantly, the negative control peptide, BDS-I[1-8scr], did not
display any pharmacological activity, thus highlighting that the
sequence of BDS-I[1-8] is essential for the inhibitory effect of
BDS-I on KV3.4 activity. The BDS-I[1-8], similarly to BDS-I, was
able to selectively inhibit the fast inactivating K+ currents carried
by the KV3.4 also in NGF-differentiated PC-12 cells, a well-
known in vitro model mimicking the neuronal system, whereas
BDS-I[1-8scr] did not exert any effect. More interestingly,
BDS-I[1-8], but not BDS-I[1-8scr], fully counteracted the
Aβ1−42-induced enhancement of KV3.4 activity and prevented
Aβ1−42-induced caspase-3 activation and abnormal nuclear
morphology. Indeed, we previously demonstrated that Aβ1−42
peptide induces a significant increase in KV3.4 expression and
activity in NGF-differentiated PC-12 cells and hippocampal
neurons and that BDS-I, by blocking KV3.4 channels, prevents
the apoptotic cascade triggered by Aβ1−42 (Pannaccione et al.,
2005, 2007). The present study clearly shows that, similarly
to BDS-I, BDS-I[1-8] is able to exert a neuroprotective effect
by counteracting the upregulation of KV3.4 channel induced
by Aβ1−42.
Importantly, it has been widely demonstrated that the
dysregulation of KV3.4 channel subunits contributes to neuronal
and glial alterations in AD. Previous evidence has shown that
the overexpression of KV3.4 channel subunits, occurring both
in the early and in the advanced stages of the disease, is
crucially involved in the development of the disease (Angulo
et al., 2004). KV3.4 upregulation has also been related to
amyloid pathology, as high levels of these subunits have
been detected in amyloid plaques in post-mortem human
brain tissues (Angulo et al., 2004). Accordingly, we recently
demonstrated that the expression and function of KV3.4
channel subunits are precociously upregulated in cultured
astrocytes exposed to Aβ oligomers and in reactive astrocytes
of AD Tg2576 mice (Boscia et al., 2017). Indeed, our results
suggest that the upregulation of KV3.4 channel subunits in
astrocytes may be an early event in the AD brain, since
we observed astrocytes accumulating Aβ and overexpressing
KV3.4 subunits in cortex, hippocampus, and cerebellum of 6
month old Tg2576 mice (Boscia et al., 2017). All together,
these evidence identify KV3.4 channels as a crucial player and,
hence, as a possible pharmacological target in AD. On the
other hand, KV3.4 has been implicated in several diseases,
including cancer and cardiovascular pathologies. In particular,
it has been reported that KV3.4 channels play a key role in
cancer cell migration and invasion as BDS, similarly to KV3.4
silencing, was able to reduce the number of invasive cells (Song
et al., 2018). Moreover, KV3.4 currents have been implicated
in the proliferation of vascular smooth muscle cells, a crucial
Frontiers in Chemistry | www.frontiersin.org 9 July 2019 | Volume 7 | Article 479
Ciccone et al. BDS-I[1-8] as New Kv3.4 Inhibitor
factor underlying the unwanted remodeling of arterial walls
in pathological conditions (Miguel-Velado et al., 2010). In
this scenario, the identification of the key residues of BDS-
I essential for the inhibition of KV3.4 currents, namely BDS-
I[1-8] peptide, provides a possible therapeutic opportunity for
several diseases, despite subsequent approaches are needed
to test BDS-I[1-8] stability and efficacy in vivo. Indeed, this
small peptide could be a suitable lead compound for the
development of new therapies targeting KV3.4 not only in
neurodegeneration and neuroinflammation, but also in cancer
and other pathological conditions.
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